Relief Therapeutics Holding AG (RLFTF)

[C504]

from the following PR dated March 29

https://www.prnewswire.com/news-releases/neurorx-announces-zyesami-aviptadil-rlf-100-met-the-primary-endpoint-of-its-phase-2b3-clinical-trial-and-also-demonstrated-a-meaningful-benefit-in-survival-from-critical-covid-19-301257291.html

third paragraph:

On the basis of these findings, NeuroRx plans to apply immediately to the United States Food and Drug Administration ("FDA") for Emergency Use Authorization (EUA) and to subsequently submit a New Drug Application (NDA).

I believe also when Dr. Javitt was on the last conference call he stated they would filing for EUA that same week. I think the conference call was also on March 29.